| . | Normothermia, n (%) . | Hypothermia, n (%) . | Ratio (95% CI) . |
|---|---|---|---|
| This study | |||
| Total | 84 | 78 | |
| Died | 29 (34.5%) | 22 (28.2%) | 0.82 (0.52–1.29) |
| Neurological abnormality | 30 (35.7%) | 26 (33.3%) | 0.93 (0.61–1.43) |
| Normal survivor | 25 (29.8%) | 30 (38.5%) | 1.29 (0.84–1.99) |
| Previous study [6] | |||
| Total | 62 | 62 | |
| Died | 6 (9.7%) | 3 (4.8%) | 0.50 (0.13–1.91) |
| Neurological abnormality | 25 (40.3%) | 10 (16.1%) | 0.40 (0.21–0.76) |
| Normal survivor | 31 (50.0%) | 49 (79.0%) | 1.58 (1.19–2.09) |
| Meta-estimate | |||
| Normal survivor | 1.49 (1.18–1.88) | ||
| . | Normothermia, n (%) . | Hypothermia, n (%) . | Ratio (95% CI) . |
|---|---|---|---|
| This study | |||
| Total | 84 | 78 | |
| Died | 29 (34.5%) | 22 (28.2%) | 0.82 (0.52–1.29) |
| Neurological abnormality | 30 (35.7%) | 26 (33.3%) | 0.93 (0.61–1.43) |
| Normal survivor | 25 (29.8%) | 30 (38.5%) | 1.29 (0.84–1.99) |
| Previous study [6] | |||
| Total | 62 | 62 | |
| Died | 6 (9.7%) | 3 (4.8%) | 0.50 (0.13–1.91) |
| Neurological abnormality | 25 (40.3%) | 10 (16.1%) | 0.40 (0.21–0.76) |
| Normal survivor | 31 (50.0%) | 49 (79.0%) | 1.58 (1.19–2.09) |
| Meta-estimate | |||
| Normal survivor | 1.49 (1.18–1.88) | ||
CI, confidence interval.
| . | Normothermia, n (%) . | Hypothermia, n (%) . | Ratio (95% CI) . |
|---|---|---|---|
| This study | |||
| Total | 84 | 78 | |
| Died | 29 (34.5%) | 22 (28.2%) | 0.82 (0.52–1.29) |
| Neurological abnormality | 30 (35.7%) | 26 (33.3%) | 0.93 (0.61–1.43) |
| Normal survivor | 25 (29.8%) | 30 (38.5%) | 1.29 (0.84–1.99) |
| Previous study [6] | |||
| Total | 62 | 62 | |
| Died | 6 (9.7%) | 3 (4.8%) | 0.50 (0.13–1.91) |
| Neurological abnormality | 25 (40.3%) | 10 (16.1%) | 0.40 (0.21–0.76) |
| Normal survivor | 31 (50.0%) | 49 (79.0%) | 1.58 (1.19–2.09) |
| Meta-estimate | |||
| Normal survivor | 1.49 (1.18–1.88) | ||
| . | Normothermia, n (%) . | Hypothermia, n (%) . | Ratio (95% CI) . |
|---|---|---|---|
| This study | |||
| Total | 84 | 78 | |
| Died | 29 (34.5%) | 22 (28.2%) | 0.82 (0.52–1.29) |
| Neurological abnormality | 30 (35.7%) | 26 (33.3%) | 0.93 (0.61–1.43) |
| Normal survivor | 25 (29.8%) | 30 (38.5%) | 1.29 (0.84–1.99) |
| Previous study [6] | |||
| Total | 62 | 62 | |
| Died | 6 (9.7%) | 3 (4.8%) | 0.50 (0.13–1.91) |
| Neurological abnormality | 25 (40.3%) | 10 (16.1%) | 0.40 (0.21–0.76) |
| Normal survivor | 31 (50.0%) | 49 (79.0%) | 1.58 (1.19–2.09) |
| Meta-estimate | |||
| Normal survivor | 1.49 (1.18–1.88) | ||
CI, confidence interval.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
